This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

This database contains 145 studies, archived under the term: "patients"

Click here to filter this large number of results.

Do patients diagnosed with Alzheimer’s disease benefit from a psycho-educational programme for family caregivers? A randomised controlled study
Objective: The Aide dans la Maladie d’Alzheimer (AIDMA) study was conducted to determine whether a psycho-educational programme (PEP) for primary caregivers in addition to standard anti-dementia drugs for patients improves caregivers’ psychological condition and patients’ activities of daily life.; Method: Multicentre randomised controlled intervention trial. One hundred and sixty-seven dyads ‘patient-caregiver’ were recruited from 15 […]

Neuromidin in mixed vascular and Alzheimer’s dementia
The efficacy of neuromidin (ipidacrinum), a nonselective inhibitor of acetylcholinesterase and butyrilcholinesterase was studied in patients with mixed vascular and Alzheimer’s dementia of mild and moderate severity. Thirty patients of the main group received neyromidin in dosage 80 mg/day during 3 months; 10 patients of the comparison group matched by age, sex and severity of […]

Tolerability and efficacy of memantine add-on therapy to rivastigmine transdermal patches in mild to moderate Alzheimer’s disease: a multicenter, randomized, open-label, parallel-group study
Objective: To compare the tolerability and efficacy of combination therapy of memantine plus rivastigmine patch with rivastigmine patch monotherapy in patients with mild to moderate Alzheimer’s disease (AD).; Research Design and Methods: In this multicenter, randomized, open-label study, patients entered an 8-week run-in period (a 5 cm 2 rivastigmine patch for 4 weeks, then a […]

Parallel improvement of cognitive functions and P300 latency following donepezil treatment in patients with Alzheimer’s disease: a case-control study
Purpose: To evaluate the effect of donepezil, one of the cholinesterase inhibitors, on P300 measurements in patients with Alzheimer’s disease (AD) and investigate the relationship between the subfactors of cognitive performance and P300 components.; Methods: One hundred outpatients with AD were evaluated for cognitive function (cognitive ability screening instrument) and event-related potentials before and after […]

The Verbal Clock Test: preliminary validation of a brief, vision- and motor-free measure of executive function in a clinical sample
Assessment of executive functions is frequently time-consuming, and although some brief measures exist they are subject to problems associated with limited education, culture of origin, impairments of motor or visual systems, and tolerability. Preliminary validation of a newly developed measure, the Verbal Clock Test (VCT), was conducted in a clinical sample of 294 patients who […]

Safety and effectiveness of donepezil on behavioral symptoms in patients with Alzheimer disease
The objective of this study was to evaluate the prevalence and treatment responsiveness of neuropsychiatric symptoms in patients with mild to moderately severe Alzheimer disease recruited in a naturalistic treatment setting in Spain. All the patients, who matched the prescribing recommendations for donepezil and were able to participate in the study, received donepezil (5 to […]

Effect of TTP488 in patients with mild to moderate Alzheimer’s disease
Background: TTP488, an antagonist at the Receptor for Advanced Glycation End products, was evaluated as a potential treatment for patients with mild-to-moderate Alzheimer’s disease (AD). A previous report describes decreased decline in ADAS-cog (delta = 3.1, p = 0.008 at 18 months, ANCOVA with multiple imputation), relative to placebo, following a 5 mg/day dose of TTP488. Acute, reversible cognitive […]

Gait changes with anti-dementia drugs: a prospective, open-label study combining single and dual task assessments in patients with Alzheimer’s disease
Background: No comparison of anti-dementia drugs-related gait changes has been previously conducted combining single and dual task assessments.; Objectives: (1) To quantify and compare gait changes among patients with possible or probable Alzheimer’s disease before and after the use of acetylcholinesterase inhibitors (i.e., donepezil, galantamine, rivastigmine) or memantine, and among controls with possible or probable […]

Learning to live with a loved one with mild cognitive impairment: effectiveness of a waiting list controlled trial of a group intervention on significant others’ sense of competence and well-being
This controlled study examines the efficacy of a comprehensive group program aimed at care partners of patients with mild cognitive impairment (MCI), which comprises elements of psychoeducation, cognitive rehabilitation, and cognitive behavioral therapy. Pre- and posttreatment quantitative and qualitative data were collected in the significant others of 84 patients with MCI, 27 of whom had […]

The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial
Background: Data from 12-week placebo-controlled trials have led to mounting concerns about increased mortality in patients with Alzheimer’s disease (AD) who are prescribed antipsychotics; however, there are no mortality data from long-term placebo-controlled trials. We aimed to assess whether continued treatment with antipsychotics in people with AD is associated with an increased risk of mortality.; […]

Try searching our database by another keyword...

To make a new query of the database, please enter your search terms below:

�

Contact Us